Ultragenyx Pharmaceutical (RARE) Minority Interest (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 4 years of Minority Interest data on file, last reported at $7.0 million in Q1 2026.

• Minority Interest for Q1 2026 came in at $7.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.0 million (changed 0.0% YoY), and the FY2025 annual result was $7.0 million, changed 0.0% from the prior year.
• Minority Interest steadied at $7.0 million in Q1 2026 per RARE's latest filing, from $7.0 million in the prior quarter.
• Over five years, Minority Interest peaked at $7.0 million in Q3 2024 and troughed at $7.0 million in Q3 2024.
• A 3-year average of $7.0 million and a median of $7.0 million in 2024 frame the typical range for Minority Interest.
• On a YoY basis, Minority Interest climbed as much as 0.0% in 2025 and fell as far as 0.0% in 2025.
• A 3-year view of Minority Interest shows it stood at $7.0 million in 2024, then changed by 0.0% to $7.0 million in 2025, then changed by 0.0% to $7.0 million in 2026.
• Business Quant data shows RARE's Minority Interest at $7.0 million in Q1 2026, $7.0 million in Q4 2025, and $7.0 million in Q3 2025.